The digital health developer Evidation plans to expand its symptom-logging platform into migraine headaches with the goal of better illustrating their impacts on a person’s daily life.

Jazz Pharmaceuticals hit a bum note Thursday, reporting the failure of a phase 2b essential tremor trial to meet its primary endpoint. But the drugmaker saw numeric improvements and is waiting on the data from another study rather than immediately bringing the curtain down on the program.

Johnson & Johnson MedTech is taking a step closer toward its goal of delivering a new generation of surgery—where analytics and patient data can be automatically translated into informative feedback.

Need to order supplies, track samples or get protocol-specific support for your clinical trial in the wee hours of the morning? Labcorp is offering a software package for investigator sites that it claims can do all this and more.

Taysha Gene Therapies has unfurled more data in the developmental disorder Rett syndrome, linking its gene therapy to improvements in the first adults and children to receive low doses of the candidate.

Marea Therapeutics has emerged with $190 million, a mid-stage clinical program and a plan to harness genetics and pioneer “the next frontier” of cardiometabolic medicines.

The FDA has placed three trials of Zentalis’ WEE1 candidate on partial hold in the wake of two deaths that are presumed to be from sepsis.

Ancient plant compounds called artemisinins were the original anti-malaria heroes, but new research suggests drugs based on them may have the potential to treat a different condition entirely: polycystic ovary syndrome (PCOS).

Johnson & Johnson MedTech’s orthopedics division, DePuy Synthes, has claimed an FDA clearance for its Velys surgical robot that expands its use into partial knee replacements.

Siemens Healthineers received European approval for a blood test designed to help predict the risk of recurrence among patients with relapsing multiple sclerosis.